The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial ifarction

Suree Lekawanvijit, Sirinart Kumfu, Bing Hui Wang, Minako Manabe, Fuyuhiko Nishijima, Darren James Kelly, Henry Krum, Andrew Richard Kompa

Research output: Contribution to journalArticleResearchpeer-review

31 Citations (Scopus)


An accelerated progressive decline in renal function is a frequent accompaniment of myocardial infarction (MI). Indoxyl sulfate (IS), a uremic toxin that accumulates from the early stages of chronic kidney disease (CKD), is contributory to both renal and cardiac fibrosis. IS levels can be reduced by administration of the oral adsorbent AST-120, which has been shown to ameliorate pathological renal and cardiac fibrosis in moderate to severe CKD. However, the cardiorenal effect of AST-120 on less severe renal dysfunction in the post-MI setting has not previously been well studied. MI-induced Sprague-Dawley rats were randomized to receive either AST-120 (MI+AST-120) or were untreated (MI+Vehicle) for 16 weeks. Serum IS levels were measured at baseline, 8 and 16 weeks. Echocardiography and glomerular filtration rate (GFR) were assessed prior to sacrifice. Renal and cardiac tissues were assessed for pathological changes using histological and immunohistochemical methods, Western blot analysis and real-time PCR. Compared with sham, MI+Vehicle animals had a significant reduction in left ventricular ejection fraction (by 42 , p
Original languageEnglish
Pages (from-to)1 - 10
Number of pages10
JournalPLoS ONE
Issue number12 (Art. ID: e83687)
Publication statusPublished - 2013

Cite this